Researchers at the University of Arizona R. Ken Coit College of Pharmacy have developed a new strategy that helps the immune ...

The higher-order architecture observed in biological systems, like viruses, is very effective in nucleic acid transport. The replications of this system has been attempted with both synthetic and ...

Chronic hepatitis B (CHB) remains a significant global health burden, with existing therapies including nucleos(t)ide analogs, interferon, siRNA, and therapeutic vaccines demonstrating limited success ...

A non-transgenic approach based on RNA interference was employed to induce protection against tomato mosaic virus (ToMV) infection in tomato plants. dsRNA molecules targeting the cp gene of ToMV were ...

The deal with ADARx expands AbbVie’s siRNA focus. Image credit: hapabapa / iStock Editorial via Getty Images. · Pharmaceutical Technology · hapabapa / iStock Editorial via Getty Images. The above ...

PHILADELPHIA/NEW YORK, Oct 30 (Reuters) - Merck & Co. Inc. on Monday said it agreed to acquire biotechnology firm Sirna Therapeutics Inc. for $1.1 billion in cash to gain a stronger foothold in the ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

The discovery of siRNA and its role in RNAi was a groundbreaking finding in the field of molecular biology. In 1998, Andrew Fire and Craig Mello published a seminal paper describing the phenomenon of ...

Small interfering RNA (siRNA) drugs are a class of therapeutic agents that silence specific genes associated with inherited diseases. However, siRNA drugs have challenges because siRNAs often silence ...

The concept of RNA interference (RNAi) was raised in 1998 and is a naturally occurring defense mechanism against exogenous nucleic acid invasion and control of gene expression. Soon thereafter, small ...

In a study published in Cell Reports Physical Science on Nov. 25, a research team reported the development of an innovative intelligent light-guided biohybrid system, the CTPA/siCSF1R system, to ...

Two start-ups have launched to develop next-generation drugs using small interfering RNA (siRNA) to silence genes. The first, Judo Bio, is a spin-off of the venture capital firm Atlas Venture. The ...